TriLink BioTechnologies, a Maravai LifeSciences company, has signed a non-exclusive license and supply agreement with Lonza. According to the terms of the agreement, TriLink will supply its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
- Craig-Hallum bullish on Maravai Lifesciences, initiates with a Buy
- Maravai Lifesciences initiated with a Buy at Craig-Hallum
- Applied DNA Sciences enters manufacturing agreement with Alphazyme
- Maravai LifeSciences Announces March 2024 Investor Conference Schedule